Tag: Glutamate modulator

Riluzole was the first drug approved by the FDA for the treatment of amyotrophic lateral sclerosis (ALS) in 1995 [1.8.2]. While it remains a cornerstone of ALS therapy, the question arises: **is riluzole only used for ALS**, or does its unique mechanism hold promise for other conditions?

Originally developed as a novel glutamate modulator, troriluzole has seen varied results across different clinical trials. This article specifically addresses the question: **how effective is troriluzole?** by examining its performance in studies for spinocerebellar ataxia (SCA) and other neurological conditions.

Glutamate is the most abundant excitatory neurotransmitter in the human body, but its dysregulation is linked to numerous neurodegenerative diseases [1.2.1]. So, what is the mechanism of action of troriluzole? This third-generation prodrug primarily works by modulating and normalizing synaptic glutamate levels [1.3.1, 1.2.2].